




Searching News Database: EMD Serono
HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 13 Feb 2020
INVO Bioscience Announces Appointment of Inger Britt Carlsson as VP of Medical Affairs
INVO Bioscience Announces Appointment of Inger Britt Carlsson as VP of Medical Affairs
HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
HSMN NewsFeed - 20 Dec 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
HSMN NewsFeed - 31 Aug 2018
Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America
Rehan Verjee to Lead EMD Serono as Company Advances its Innovative Medicines Strategy in North America
HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
HSMN NewsFeed - 3 Apr 2018
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer
HSMN NewsFeed - 6 Mar 2018
Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs
Wendy Sussman Joins EMD Serono as Vice President of U.S. Healthcare Government & Public Affairs
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 4 Dec 2017
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
HSMN NewsFeed - 1 Dec 2017
EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North America
EMD Serono Appoints Zhen Su, M.D., MBA to Chief Medical Officer, North America
HSMN NewsFeed - 9 Nov 2017
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
HSMN NewsFeed - 23 Oct 2017
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
EMD Serono Appoints Robert Truckenmiller to Senior Vice President of Market Access & Customer Solutions
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 13 Jan 2017
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
Merck KGaA, Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration Partnership
HSMN NewsFeed - 6 Jan 2017
Viking Therapeutics Announces Senior Level Appointments to Management Team
Viking Therapeutics Announces Senior Level Appointments to Management Team
HSMN NewsFeed - 7 Oct 2016
Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer
Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer
HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
HSMN NewsFeed - 6 Apr 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy test for Colorectal Cancer Patients
HSMN NewsFeed - 18 Dec 2015
ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
HSMN NewsFeed - 27 May 2015
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
Zafgen Appoints Global Head of Medical Affairs and Global Head of Regulatory
HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
HSMN NewsFeed - 12 Aug 2014
AMAG Pharmaceuticals Appoints Robert Blood as Vice President of Legal Affairs and Chief Compliance Officer
AMAG Pharmaceuticals Appoints Robert Blood as Vice President of Legal Affairs and Chief Compliance Officer
HSMN NewsFeed - 31 Mar 2014
New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer
New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer
HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
HSMN NewsFeed - 31 Jan 2014
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
HSMN NewsFeed - 9 Jan 2014
OvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations
OvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations
HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 8 Nov 2013
EMD Serono Announces Appointment of Paris Panayiotopoulos as President and Managing Director
EMD Serono Announces Appointment of Paris Panayiotopoulos as President and Managing Director
HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 3 Feb 2011
Theratechnologies and Ferrer Announce a Distribution & Licensing Agreement for Tesamorelin in Europe
Theratechnologies and Ferrer Announce a Distribution & Licensing Agreement for Tesamorelin in Europe
HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
HSMN NewsFeed - 18 Jan 2010
Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
HSMN NewsFeed - 17 Dec 2009
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 10 Jun 2008
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin America
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 16 Apr 2008
Merck Announces Planned Investment of $50 Million in Research Center in the US
Merck Announces Planned Investment of $50 Million in Research Center in the US
HSMN NewsFeed - 7 Nov 2007
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)